The changing pattern of antibiotic resistance of Neisseria gonorrhoeae
The World Health Organisation has just issued the conclusions of a consultation on sexually transmitted diseases treatment strategies.' This replaces the previous consultative report issued in 1983.2 The recommendations for the treatment of gonorrhoea in these two reports are very different. In 1983 the recommended regimen was either single dose therapy with an injectable or oral penicillin combined with probenecid, or a course of a tetracycline. Spectinomycin or cefoxitin were recommended as alternatives where penicillinase producing Neisseria gonorrhoeae (PPNG) or other resistant gonococci were known to be prevalent. Resistance was treated very much as an emergency issue with some recognised problem areas in South East Asia and Africa. Now, seven years later gonococcal resistance to antibiotics is a problem in many parts of the world. The new recommended standard regimens are single dose ceftriaxone 250 mg i.m., ciprofloxacin 500 mg oral, or spectinomycin 2 g i.m. Tetracyclines and oral or injectable penicillins are now only recommended where the level of resistance to these agents is known to be low.
Despite their relatively high initial cost, these three regimens were proposed on the principle that the overall cost of cheaper, less effective regimens (including relapse, complications, further spread and increasing resistance) would in fact be greater. The ceftriaxone and ciproflaxacin doses are higher than those used in some quarters, but it was felt that the higher doses would be more effective in preventing the emergency and spread of resistance to both agents.
Antimicrobial resistance in N gonorrhoeae may be controlled by genes on either plasmid or chromosome. Clinically significant chromosomal resistance to Gonococcal rates ofresistance to antibiotics appear to be highest in Africa, South East Asia and parts of the Pacific. Itis in these regions where the lack of any regular data collection about patterns of gonococcal resistance and the possible emergence of new forms of resistance is most serious. Without such information it is impossible to think about coherent strategies for controlling the spread of resistant strains and maintaining the efficacy of current antimicrobial therapies.
The problem is two-fold. First, lack of resources and expertise. Adequate facilities, training and support need to be provided to enable a few laboratory centres in these areas to carry out systematic gonococcal susceptibility testing. Second, the establishment of a world wide network into which all laboratories with such data can feed their information and receive in return a timely summary of trends world wide. The need for some such system of surveillance for gonococcal susceptibility to antimicrobial agents has been stated repeatedly by WHO working groups and expert committees and the WHO is the ideal organisation to provide such co-ordination. There are precedents with other micro-organisms.
At present third generation cephalosporins and related compounds, spectinomycin and fluoroquinolones provide good cover for resistant strains of Ngonorrhoeae. However, there are actual or potential resistance problems with all three, which without careful control will grow. At 
